2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Vassiliki Papadimitrakopoulou, MD, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.
Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.
Pembrolizumab is currently being studied in patients whose tumors express PD-L1. This is a smart enrichment strategy for treating patients, Papadimitrakopoulou says, and the activity seen so far could be because of this selection. However, all evidence so far points to good activity with this agent in all settings of non-small cell lung cancer.